Tirzepatide for Obesity Treatment and Diabetes Prevention
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [76]
In the citing paper
“Tirzepatide administered at doses of 5, 10, and 15 mg once weekly in adjunct with a behavioral intervention comprising an energy-deficit diet and increased physical activity appears to be even more effective, with absolute weight losses of 15.0%, 19.5%, and 20.9% after 72 weeks in the SURMOUNT-1 trial 31 that was largely maintained when treatment was continued in a subset of participants for 176”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“SURMOUNT-1 showed the NNT with tirzepatide to prevent one case of T2D was 9 patients.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [62]
In the citing paper
“the reversal in glycemic benefits in HbA1c and FSG were observed early on within 16 weeks of withdrawing tirzepatide likely due to the known direct glucose-lowering effect of tirzepatide”
From Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (2026) · cites this paper as [18]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citation2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Cited by
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634
Self-citationWest, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
Blüher, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16263 · Cited by 175
“Whether weight loss strategies can reduce the incidence of obesity-related cancers needs to be systematically investigated in prospective studies.”
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Theodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 175
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504214 · Cited by 110
Self-citationMcGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03978-z · Cited by 100
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 140
Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update
Pedersen, S. D., Manjoo, P., Dash, S., Jain, A., Pearce, N., & Poddar, M. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.250502 · Cited by 78
The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome
Janssen, J. A. M. J. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413238 · Cited by 84
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 167
Mutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“At 3 years of follow-up, tirzepatide use led to a sustained mean loss of weight of 20% with less likelihood of deterioration to diabetes in persons with obesity and prediabetes when compared to placebo [137].”
InfluentialGaneshalingam, A. A., Uhrenholt, N. G., Arnfred, S., Gæde, P., Düring, S. W., Stenager, E. N., Bünger, N., Pedersen, A. K., Bilenberg, N., & Frystyk, J. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.2332 · Cited by 78
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Budini, B., Luo, S., Tam, M., Stead, I., Lee, A., Akrami, A., Vidal-Puig, A., & Park, A. (2026) · eClinicalMedicine · doi:10.1016/j.eclinm.2026.103796 · Cited by 52
“6,7 Notably, we observed that the residual weight loss was consistently greater than that seen in placebo groups.”
Unnikrishnan, R., Shaw, J. E., Chan, J. C. N., Wild, S. H., Peters, A. L., Orrange, S., Roden, M., & Mohan, V. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00635-0 · Cited by 78
“The dual GLP1–GIP receptor agonist tirzepatide was evaluated in 2,539 individuals with overweight or obesity without diabetes mellitus, 1,032 of whom had prediabetes 141 .”
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“During the active treatment period, a new diagnosis of T2D was reported in 1.3% versus 13.3% of patients randomized to tirzepatide versus placebo 39 .”
InfluentialQuarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 67
“Indeed, as shown by the results of numerous studies, there is a subgroup of patients who have no response, a moderate response, or a favorable response [27,28,70].”
Prediabetes remission to reduce the global burden of type 2 diabetes
Sandforth, L., Kullmann, S., Sandforth, A., Fritsche, A., von Schwartzenberg, R. J., Stefan, N., & Birkenfeld, A. L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.01.004 · Cited by 59
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.21016 · Cited by 43
Horn, D. B., Linetzky, B., Davies, M. J., Laffin, L. J., Wang, H., Murphy, M. A., Zimner-Rapuch, S., Lau, E., Arad, A. D., & Lee, C. J. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6112 · Cited by 50
Tirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 43
“Adverse events (AEs) leading to medication discontinuation were reported in 7.3– 12.3% of tirzepatide users versus 5.9% for placebo [51].”
InfluentialTheodorakis, N., & Nikolaou, M. (2025) · Biomedicines · doi:10.3390/biomedicines13010135 · Cited by 50
“Regarding glycemic control, tirzepatide showed a mean HbA1c reduction of about − 2.1% vs. − 0.5% in placebo ( p 0.001) [29].”
InfluentialO'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Reddy, Y. N. V., Frantz, R. P., Hemnes, A. R., Hassoun, P. M., Horn, E. M., Leopold, J. A., Rischard, F. P., Rosenzweig, E. B., Hill, N. S., ERZURUM, S. C., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.530 · Cited by 45
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 106
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Self-citationGLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 43
Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0014 · Cited by 29
“In recent, usually short-term clinical trials, other medications, including glucagon-like peptide 1 (GLP-1) receptor agonists, have reduced the incidence of T2D (26,27).”
Self-citationBailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“Both semaglutide and tirzepatide can also reduce progression of pre-diabetes to diabetes in obese individuals [13,19].”
Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease
Li, Y., Li, D., Lin, J., Zhou, L., Yang, W., Yin, X., Xu, C., Cao, Z., & Wang, Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02670-3 · Cited by 35
Malhotra, A., Grunstein, R., Azarbarzin, A., Sands, S. A., Somers, V. K., Aronne, L. J., Jastreboff, A. M., Lou, J., Chakladar, S., Dunn, J. P., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04071-1 · Cited by 52
“The tirzepatide-associated change in hsCRP was significantly”
Self-citationDavies, M. J., Lim, S. K., Slater, T., Goldney, J., Philis‐Tsimikas, A., Franco, D. R., Lamptey, R., Yates, T. E., Tankova, T. I., & Lingvay, I. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00687-w · Cited by 63
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention
Ostrominski, J. W., CHENG, A. Y. Y., Nelson, A. J., Neuen, B. L., Sattar, N. A., Tuttle, K. R., & Vaduganathan, M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01384-4 · Cited by 35
Hankosky, E. R., Chinthammit, C., Meeks, A., Huang, A., Ward, J. M., Mojdami, D., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16290 · Cited by 39
“50 The cardiovascular benefits and impact of tir-zepatide on progression to T2D are being investigated in a large, international, phase 3 study in people with obesity or overweight without T2D (SURMOUNT-MMO).”
The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
Flint, S. W., Vázquez‐Velázquez, V., Brocq, S. L., & Brown, A. C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16255 · Cited by 35
Clinical Impact of Tirzepatide on Patients With OSA and Obesity
Wu, J., Chen, C., Tu, W.-L., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Hung, K., Yu, T., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.03.030 · Cited by 26
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Valderas, E. G., Arad, A. D., Das, S., Dunn, J. P., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00656-2 · Cited by 52
Self-citationStoll, F., Kantowski, T., Laaser, J., Kloiber, U., Plitzko, G., Mann, O., Aberle, J., & Lautenbach, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.02.004 · Cited by 20
Wu, J., Chan, S., Hsu, W., Kuo, C., Tsai, Y., Liu, T., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16353 · Cited by 22
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“Recently, the 3-year safety outcomes of the SURMOUNT-1 trial with tirzepa-tide (dual GIP/GLP-1 RA) were reported, confirming its efficacy in reducing weight and delaying progression to T2D in persons with both obesity and prediabetes [58].”
Beyond Glucose—Rethinking Prediabetes for Precision Prevention
Wagner, R. J., Selvin, E., Sehgal, R., Prystupa, K., Misra, S., Fritsche, A., & Heni, M. (2025) · Diabetes Care · doi:10.2337/dci25-0054 · Cited by 31
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Sattar, N. A., García‐Pérez, L., Rodríguez, Á., Kapoor, R., Stefański, A., & Hankosky, E. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16549 · Cited by 28
“27 These results are consistent with a post hoc risk prediction modelling study demonstrating that tirzepatide treatment was associated with reduced 10-year predicted risk of developing T2D (either among people with prediabetes at baseline or regardless of prediabetes status at baseline).”
InfluentialSelf-citationSouto, M., Gonçalves, T. C., & Cotter, J. B. (2025) · Nutrients · doi:10.3390/nu17142310 · Cited by 26
Subphenotype-Dependent Benefits of Bariatric Surgery for Individuals at Risk for Type 2 Diabetes
Sandforth, L., Raverdy, V., Sandforth, A., Bauvin, P., Chatelain, E., Verkindt, H., Mingrone, G., Guidone, C., Verrastro, O., Zhou, K., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0160 · Cited by 17
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Hankosky, E. R., Desai, K. R., Chinthammit, C., Grabner, M., Stockbower, G. E., He, X., Mojdami, D., Wenziger, C. M., & Gibble, T. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101636 · Cited by 21
Tang, H., Lu, Y., Zhang, B., Zhou, T., Zhang, D., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70054 · Cited by 28
Effect of GLP-1 receptor agonists on body composition
Bhandarkar, A. P., Bhat, S., & Kapoor, N. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000934 · Cited by 29
Dagogo-Jack, S. E. (2025) · Diabetes · doi:10.2337/dbi25-0006 · Cited by 28
Nissen, S. E., Wolski, K., D’Alessio, D. A., Weerakkody, G. J., Kiljanski, J. I., Wiese, R. J., Pavo, I. J., Cariou, B., & Nicholls, S. J. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0767 · Cited by 25
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Recent findings from the SURMOUNT-1 trial in 1032 predia-betic subjects showed a 94% reduction in T2D progression risk over 3 years and 4 months [182 ].”
Siebert, S., Sattar, N. A., & Ferguson, L. D. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105904 · Cited by 21
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Khunti, K., Papamargaritis, D., Aroda, V. R., Anjana, R. M., & Kashyap, S. R. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00134-2 · Cited by 22
Obesity-Related Glomerulosclerosis—How Adiposity Damages the Kidneys
Zbrzeźniak, J., Winiarska, A., Perkowska‐Ptasińska, A., & Stompór, T. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136247 · Cited by 23
“Mean percent change in body weight at week 52 was − 13.6% and − 17.5% with tirzepatide 10 mg and 15 mg, respectively, compared with − 2.3% with the placebo [97].”
InfluentialArd, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 28
“12 Some guidelines for the management of obesity suggest discontinuing OMMs that fail to produce at least a 5% weight reduction within 12 weeks.”
Self-citationMari, A., Stefański, A., van Raalte, D. H., Ma, X., LaBell, E. S., Fan, L., Lee, C. J., Thomas, M. K., Bunck, M. C. M., & Ferrannini, E. (2025) · Diabetes Care · doi:10.2337/dc25-0763 · Cited by 23
Self-citationTian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
Luu, S., Chan, D. E. C. Y., Marshall, N. S., Phillips, C. L., Grunstein, R. R., & Yee, B. J. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102169 · Cited by 17
Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70143 · Cited by 17
“21 In post hoc analyses from the SURMOUNT-1 primary trial (72-week), tirzepatide treatment was associated with a significant decrease in the 10-year predicted risk of ASCVD and T2D compared with placebo.”
InfluentialSelf-citationForst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Morieri, M. L., Rigato, M., Frison, V., D’Ambrosio, M., Sartore, G., Avogaro, A., & Fadini, G. P. (2025) · Diabetologia · doi:10.1007/s00125-025-06402-w · Cited by 21
Sundheim, B., Hirani, K., Blaschke, M., Lemos, J. R. N., & Mittal, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020383 · Cited by 16
“Furthermore, participants achieved an average weight reduction of 22.9%, underscoring the metabolic benefits of this therapy [131].”
InfluentialBeyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children
Zaitoon, H., Wauters, A. D., Rodríguez, L. M., & Lynch, J. L. (2025) · Children · doi:10.3390/children12111427 · Cited by 15
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Staging prediabetes and type 2 diabetes: the time to start is now
Shah, V. N., Battelino, T., Bergenstal, R. M., & Phillip, M. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00333-x · Cited by 12
Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer
Tatum, K. L., Dahman, B. A., Stevenson, A., Williford, S. E., Cassel, J. B., Zhao, H., Shen, J., McGuire, K. P., Diala, O. R., Oladimeji, R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.12133 · Cited by 20
Diabetes, obesity, and cardiovascular disease—what is the impact of lifestyle modification?
Seth, C. M., Schmid, V., Mueller, S., Haykowsky, M. J., Foulkes, S., Halle, M., & Wernhart, S. (2025) · Herz · doi:10.1007/s00059-025-05309-x · Cited by 15
Adiposity at the core of the rising tide of young-onset type 2 diabetes worldwide
Sattar, N. A., & Misra, A. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103249 · Cited by 12
Shukla, A. P., Dunn, J. P., Valderas, E. G., Fraseur, J. G., Karanikas, C. A., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70215 · Cited by 18
“44 Similarly in SURMOUNT-2 in participants with obesity and T2D, greater improvements in health-related quality of life were observed particularly among those who achieved greater body weight reduction or had physical function limitations at base-line.”
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“Several lines of evidence suggest that bringing prediabetic (intermediate hyperglycemia) glucose values back to normoglycemia may have beneficial effects (74, 78, 79), a notion that clearly needs to be formally proven.”
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
“After the 17-week off-treatment period, the tirzepatide group maintained a weight reduction of − 17.3% ( − 18.7 kg) relative to baseline [33].”
InfluentialIncretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
Koceva, A., Janež, A., & Jensterle, M. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102038 · Cited by 17
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“Notably, tirzepatide, like semaglutide, also reduced the risk of progression to T2DM compared to placebo over the study period [82].”
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“…receptor (GIPR)– GLP1R co-agonist, has shown greater weight-lowering efficacy in people with obesity than semaglutide, reaching mean placebo-corrected weight loss in the region of 15–20% 14,18 , and additional benefits on certain obesity-related complications 19,20 and diabetes prevention 21 .”
InfluentialGupta, N., Babyak, A., Chorbajian, A., Tardio, V., Ballreich, J. M., & Dasgupta, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16627 · Cited by 11
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C. J., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J., Selzer, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03609 · Cited by 20
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
“…of observation in the SELECT RCT. 72 Tirzepatide 15 mg led to a 93% T2D reduction associated with 19.7% wt reduction in the 3 year SURMOUNT-1 extension study 73 ; this T2D prevention benefit may reflect incretin effects of the GLP-1 component and GIP bioeffects in addition to weight reduction.”
InfluentialFrom needles to pills: oral GLP-1 therapy enters the obesity arena
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00245-5 · Cited by 13
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
“Furthermore, tirzepatide, a novel dual GIP/GLP-1 RA, has shown remarkable efficacy in the management of obesity, in delaying the onset of T2DM among individuals with prediabetes, in reducing HbA1c levels, and improving obesity-related obstructive sleep apnea (OSA) [179,180].”
Wadden, T., Oquendo, M. A., Kushner, R. F., Cao, D., Karanikas, C. A., Kechter, A., & Murphy, M. A. (2026) · Obesity · doi:10.1002/oby.70122 · Cited by 16
Taxifolin as a Therapeutic Potential for Weight Loss: A Retrospective Longitudinal Study
Hattori, Y., Nakaoku, Y., Ogata, S., Saitô, S., Nishimura, K., & Ihara, M. (2025) · Nutrients · doi:10.3390/nu17040706 · Cited by 12
“Obesity is an escalating public health issue and ranks as the most prevalent chronic disease globally, affecting approximately 650 million adults [1].”
Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“The incidence of type 2 diabetes was markedly lower in the tirzepatide groups versus placebo at week 176 (1.3% vs. 13.3%; HR: 0.07 (95% CI: 0.0 to 0.1), P<0.001), and this bene fi t persisted after a 17-week off-treatment period (HR: 0.12 (95% CI: 0.1 to 0.2), P<0.001) (83).”
InfluentialFadini, G. P., Giaccari, A., Broglio, F., Nollino, L., Fattor, B., Anichini, R., Meregalli, G., Avogaro, A., Consoli, A., Aimaretti, G., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101499 · Cited by 18
“11,12 An eventual refining of the definition, based on new data, can have critical implications for estimating its frequency, durability, and the prognostic meaning of achieving such a state.”
LEAP2 as a therapeutic target in obesity and cardiometabolic disorders
Holm, S. K., Johansen, V. B. I., & Clemmensen, C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-10007-4 · Cited by 11
“Indeed, both amylin and GIP analogs failed to show convincing effects in rodents [ 166–169], yet mimicking these hormones turned out to be transformative in humans when combined with GLP-1 [15, 148, 151, 152, 170, 171].”
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 15
Hoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Jastreboff et al. recently confirmed this concept in a large prevention trial, showing that tirzepatide significantly reduced the incidence of type 2 diabetes among individuals with obesity and prediabetes [44].”
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Aetiology of type 2 diabetes: an experimental medicine odyssey
Taylor, R. (2025) · Diabetologia · doi:10.1007/s00125-025-06428-0 · Cited by 10
Metadata
- Authors
- Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I.
- Affiliations
- University College Dublin (IE)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-06
- Volume
- 392
- Issue
- 10
- Pages
- 958-971
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404310616
- Semantic Scholar
- 6522eecd15e4fbb48021d492e79ee341ffc3540a
- Cited by
- 462
- References
- 41
- Citations by year
- 2026: 239 · 2025: 220
- FWCI
- 130.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, obesity, prediabetes, type 2 diabetes prevention, weight loss, GIP/GLP-1 receptor agonist, long-term safety, diabetes onset, adverse events, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Disease Progression, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.